JAMH
KPTI icon

Junson Asset Management (HK)’s Karyopharm Therapeutics KPTI Stock Holding History

Junson Asset Management (HK)’s Portfolio KPTI Stock Details KPTI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-10,000
Closed -$1.57M – 43
2021
Q1 		$1.57M Buy
10,000
+5,894
+144% +$1.24M 0.66% 41
2020
Q4 		$953K Buy
+4,106
New +$951K 0.47% 53

Other funds holding KPTI

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $74.1B AUM 71.18% 1-Year Est. Return
DMPV
Delphi Management Partners VIII San Mateo, California $138M AUM 56.74% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
FCM
Frontier Capital Management Boston, Massachusetts $10.7B AUM 67.78% 1-Year Est. Return
RHJA
Rice Hall James & Associates San Diego, California $2.05B AUM 43.16% 1-Year Est. Return

Junson Asset Management (HK)'s KPTI Position: Q2 2021 in Review

Junson Asset Management (HK) sold out of Karyopharm Therapeutics (KPTI) in Q2 2021, closing a stake of 10,000 shares — an estimated $1.57M sold.

Junson Asset Management (HK) first reported a position in KPTI in Q4 2020 and held it in 2 quarters. The position peaked at $1.57M in Q1 2021. 153 funds tracked by Wall St. Rank hold KPTI as of Q2 2021.

  • Junson Asset Management (HK) reported no remaining Karyopharm Therapeutics position as of Q2 2021 after selling out during the quarter.
  • Junson Asset Management (HK) sold 10,000 Karyopharm Therapeutics shares in Q2 2021, an estimated $1.57M.
  • Junson Asset Management (HK) first reported a position in Karyopharm Therapeutics in Q4 2020 and held it in 2 quarters.
  • Junson Asset Management (HK)'s Karyopharm Therapeutics position peaked at $1.57M in Q1 2021.
  • 153 funds tracked by Wall St. Rank held Karyopharm Therapeutics as of Q2 2021.

Based on Junson Asset Management (HK)'s 13F filing for Q2 2021, filed 13 Jul 2021.